You just read:

ProNAi Licenses Oncology Drug Targeting DNA Damage Response Checkpoint Kinase 1 (Chk1) From CRT Pioneer Fund, UK

News provided by

ProNAi Therapeutics

Sep 27, 2016, 07:15 ET